Crescent Biopharma, Inc.NASDAQ: CBIO

Crescent Biopharma Announces Grants of Inducement Awards

· Issued by Crescent Biopharma, Inc. via GlobeNewswire

Summary by 6ix AI

Crescent Biopharma, a clinical-stage biotechnology company developing cancer therapies, said the independent Compensation Committee of its Board approved, on October 5, 2026, options to buy an aggregate of 81,525 of its ordinary shares for six non-executive employees as equity inducement awards.

Key details

  • The options have a 10-year term and an exercise price of $13.94, the closing price of Crescent's ordinary shares on Nasdaq on October 5, 2026.
  • One-fourth of each employee's options vest on the first anniversary of the employee's start date, and one-forty-eighth vest monthly after that.
  • The awards were made under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended, and were material to each employee's acceptance of employment, in line with Nasdaq Listing Rule 5635(c)(4).

What’s still pending

  • Vesting depends on each employee's continuous service with Crescent through the applicable vesting dates.

6ix AI wrote this summary from the release below and checked it against the release.

Crescent Biopharma, Inc.

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares of the Company's ordinary shares to six non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on October 5, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $13.94, the closing price per share of Crescent's ordinary shares as reported by Nasdaq on October 5, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma

Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company's clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors

Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019

Crescent Biopharma, Inc. on 6ix

Earlier from Crescent Biopharma

Later from Crescent Biopharma

All Crescent Biopharma news releases